Agilent Technologies Reports Second-Quarter 2012 Results
News May 16, 2012
Agilent Technologies Inc. has reported revenues of $1.73 billion for the second fiscal quarter ended April 30, 2012, 3 percent above one year ago.
Second-quarter GAAP net income was $255 million, or $0.72 per share. Last year's second-quarter GAAP net income was $200 million, or $0.56 per share.
During the second quarter, Agilent had intangible amortization of $26 million, transformational charges of $8 million, and acquisition and integration costs of $6 million.
The company also recognized a tax benefit of $11 million. Excluding these items and $9 million of other net benefits, Agilent reported second-quarter adjusted net income of $275 million, or $0.78 per share.
Bill Sullivan, Agilent president and CEO, said, "Our second-quarter performance demonstrated our ability to deliver strong results despite a challenging economic climate."
Electronic Measurement second-quarter revenues were up 5 percent over the prior year. Orders were up 13 percent from the same period last year. Growth was driven by wireless manufacturing.
Chemical Analysis revenues were 2 percent above one year ago. Orders were up 7 percent. Growth continued in key end markets, including petrochemical and food.
Life Sciences revenues grew 1 percent over last year, while orders declined 1 percent year over year. Solid performance in pharma was offset by weakness in academia and government.
Second-quarter ROIC was 26 percent. Agilent generated $353 million of cash from operations in the quarter.
Fiscal third-quarter 2012 revenues are expected to be in the range of $1.77 billion to $1.79 billion. Fiscal third-quarter non-GAAP earnings are expected to be in the range of $0.82 to $0.84 per share.
Agilent expects full fiscal-year 2012 revenue of $6.94 billion - $7.00 billion, and a tightened range of non-GAAP earnings of $3.18 - $3.24 per share.
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE